✦ LIBER ✦

Cetuximab is Associated With Excessive Toxicity When Combined With Bevacizumab Plus mFOLFOX6 in Metastatic Colorectal Carcinoma

✍ Scribed by Allyson J. Ocean; Blase Polite; Paul Christos; Lisa Horvath; Anne Hamilton; Daniel Matulich; Helen X. Chen; Joseph A. Sparano; Hedy L. Kindler

Book ID: 119935259
Publisher: CIG Media Group, LP.
Year: 2010
Tongue: English
Weight: 135 KB
Volume: 9
Category: Article
ISSN: 1533-0028
DOI: 10.3816/ccc.2010.n.042

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase Ib Study of Drozitumab Combined Wi

Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

✍ Rocha Lima, Caio M.; Bayraktar, Soley; Flores, Aurea M.; MacIntyre, Jessica; Mon 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 223 KB

Treatment Rationale and Study Design for

Treatment Rationale and Study Design for a Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination With Bevacizumab Plus mFOLFOX-6 in Patients With Previously Untreated Metastatic Colorectal Cancer

✍ Bendell, Johanna C.; Ervin, Thomas J.; Gallinson, David; Singh, Jaswinder; Walla 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 608 KB